ClinicalTrials.gg
Status unknownNCT02871245Updated Apr 14, 2017

Clinical Trial on Acupuncture Therapy in Patients With Gastrointestinal Neoplasms Laparoscopic Surgery

An interventional study of Laparoscopic Surgery and Acupuncture treatment in Gastrointestinal Neoplasms, sponsored by Xiaonan Cui. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-04-14.

Sponsored by Xiaonan Cui · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Apr 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 110 studies in Gastrointestinal Neoplasms with a site in China — 44 open to participants now, 51 under way, 6 of them phase 3. Gastrointestinal Neoplasms · China.

Planned enrollment
43rd of 88
120 · median 120
Started
2016
with 4 others
No phase
30 of 110
10 open now
Registered
18th of 110
by date
Lead sponsor
3 of 110
Xiaonan Cui

Among the 110 studies in Gastrointestinal Neoplasms with a site in China, this one is the 43rd largest by planned enrollment of the 88 interventional ones that give a count, is one of 5 that started in 2016, is one of 30 with no phase, and was the 18th registered.

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

44 of the 110 studies in Gastrointestinal Neoplasms with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Gastrointestinal Neoplasms with a site in China, or all of them as a file.
02

Study summary

Patients accepted laparoscopic radical operation for carcinoma of colon and upper middle section of the rectum will be as the research object. Cancer patients are diagnosed based on pathology or cell biology. The trial is randomized, parallel and open. They are randomized into 2 groups: both groups receive surgery. The experimental group receives conventional treatment combine with electroacupuncture Zusanli point .etc finish operation and the contrast receives the same conventional treatment with experimental group. Clinical evaluation includes gastrointestinal tract recovery of function, pain relief, life quality improvement. Blood biochemistry tests mainly include gastrin(GAS), stress related hormone, peroxidatic reaction and the ratio of immune cells.

03

Conditions studied

  • Gastrointestinal Neoplasms

Keywords

  • Acupuncture Therapy
  • Laparoscopic Surgery
  • Gastrointestinal Tract Recovery of Function
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight: 40kg-90kg, male and female.
  • Diagnosis: imaging, cell and pathology report.
  • Brain, heart, lung, liver, kidney are at good condition in 2 weeks before surgery.
  • No conscious obstacle and limbs disability.

Exclusion criteria

Exclusion Criteria:

  • Fainting during acupuncture.
  • Electrolyte imbalance.
  • Serious and life-threatening complications after surgery.
  • In addition, patients taking part in other clinical trials, being treated with other biotherapy or immunotherapy and researchers consider not suitable for clinical subjects for other reasons will be excluded.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Comparator Group

    Patients received gastrointestinal neoplasms laparoscopic surgery but no acupuncture therapy.

    Procedure: Laparoscopic Surgery

  • Experimental
    Acupuncture Therapy Group

    Patients received gastrointestinal neoplasms laparoscopic surgery and acupuncture therapy. Finish surgery up to 24 hours electricity acupuncture treatment, treatment 1 times a day, every time lasted 30 minutes, 5 days in a row

    Procedure: Laparoscopic Surgery · Device: Acupuncture treatment

Interventions

  • ProcedureLaparoscopic Surgery
  • DeviceAcupuncture treatment
06

What researchers measure

Primary outcomes

  1. Number of participants and classification with operation-related adverse events as assessed by CTCAE v4.03.

    Time frame: day 1, day 3, day 5, day 7 after surgery

Secondary outcomes

  1. The quality of life questionnaire(QLQ).

    Assessing in 5 grade, mainly include appetite, sleep, pain,etc.

    Time frame: day 1, day 3, day 5, day 7 after surgery

  2. Stress hormone in blood.

    Estradiol (female), progesterone (female), testosterone (male)

    Time frame: day 2, day 7 after surgery

  3. Immune cell number ratio in blood.

    Th1/Th2, Th17/Treg

    Time frame: day 2, day 7 after surgery

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116011, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2016 (actual). Primary completion is estimated for May 2017, 8 months after the start.

Of 154 non-industry interventional studies with no phase under Gastrointestinal Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 8 months is below that.

Counting every sponsor, half of 164 studies reached it within 36 months; a quarter within 17 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2016
First posted
Aug 18, 2016
StartActual
Sep 21, 2016
Primary completionEst.
May 2017
CompletionEst.
Jul 2017
Last update
Apr 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02871245
Lead sponsor
Xiaonan Cui
Responsible party
Xiaonan Cui (Professor, Chief physician, The First Affiliated Hospital of Dalian Medical University) — Sponsor-investigator
First posted
Aug 18, 2016
Start date
Sep 21, 2016
Primary completion
May 2017 (estimated)
Completion
Jul 2017 (estimated)
Last update
Apr 14, 2017

Study contacts

Xiaonan Cui, MD, PhD
Contact
cxn23@sina.com
+8618098876725
Xiaonan Cui, MD, PhD
principal investigator · The First Affiliated Hospital of Dalian Medical University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion